AI Engines For more Details: Perplexity Kagi Labs You
Antioxidant Properties: Ethoxyquin exhibits antioxidant activity, which means it can neutralize free radicals and prevent oxidative damage to cells. In this regard, it may offer potential benefits for reducing oxidative stress and lowering the risk of chronic diseases associated with inflammation and oxidative damage, such as cardiovascular disease and certain cancers.
Potential Toxicity: Despite its antioxidant properties, ethoxyquin has raised concerns regarding its safety, particularly in high doses. Studies in animals have suggested potential toxic effects of ethoxyquin on the liver, kidneys, and immune system. Some research has linked ethoxyquin exposure to adverse effects such as liver damage, kidney toxicity, and immune system suppression in animals.
Regulatory Status: Ethoxyquin is regulated by government agencies, including the U.S. Food and Drug Administration (FDA), which sets limits on its use in animal feed and pet food. Regulatory agencies assess its safety based on available scientific evidence and establish maximum residue limits (MRLs) to ensure that levels of ethoxyquin in food products are within acceptable safety limits.
Animal Health: In the pet food industry, ethoxyquin has been used as an antioxidant to preserve the nutritional quality of pet food and prevent the degradation of fats. While it has been generally recognized as safe (GRAS) for use in pet food by regulatory agencies, some pet owners and veterinarians have raised concerns about potential health risks associated with long-term exposure to ethoxyquin in pet food.
Controversy and Debate: The safety of ethoxyquin in pet food has been the subject of controversy and debate within the pet food industry and among consumers. Some pet food manufacturers have opted to use alternative preservatives or natural antioxidants in response to consumer demand for "cleaner" pet food products.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.6 | 0.6 | 6.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.6 | 0.08 |
| Allergies | 6.2 | 3 | 1.07 |
| Allergy to milk products | 2.3 | 1.6 | 0.44 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 5.4 | 5.8 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.6 | 1.2 | 2 |
| Ankylosing spondylitis | 4.3 | 0.9 | 3.78 |
| Anorexia Nervosa | 1.6 | 2.6 | -0.63 |
| Antiphospholipid syndrome (APS) | 1 | 1 | |
| Asthma | 4.7 | 3.3 | 0.42 |
| Atherosclerosis | 1.5 | 1.8 | -0.2 |
| Atrial fibrillation | 3.5 | 1.7 | 1.06 |
| Autism | 9.2 | 9.1 | 0.01 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 2.1 | 1.7 | 0.24 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.6 | 3.1 | -4.17 |
| Carcinoma | 3.8 | 2.6 | 0.46 |
| Celiac Disease | 1.9 | 3.9 | -1.05 |
| Cerebral Palsy | 1.8 | 1.3 | 0.38 |
| Chronic Fatigue Syndrome | 4.7 | 6.1 | -0.3 |
| Chronic Kidney Disease | 4.4 | 2.3 | 0.91 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 1.7 | 0.6 | 1.83 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 5.9 | 2.5 | 1.36 |
| Constipation | 2 | 0.7 | 1.86 |
| Coronary artery disease | 2.1 | 1.9 | 0.11 |
| COVID-19 | 10.6 | 10.8 | -0.02 |
| Crohn's Disease | 7.3 | 5.4 | 0.35 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.9 | 1.9 | -1.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.6 | 1.4 | 0.14 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 11.1 | 9.7 | 0.14 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.4 | 0 |
| Endometriosis | 3.2 | 2.3 | 0.39 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.2 | 2.7 | 0.19 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 3.4 | 1.3 | 1.62 |
| Functional constipation / chronic idiopathic constipation | 5.2 | 3.5 | 0.49 |
| gallstone disease (gsd) | 2.9 | 1.2 | 1.42 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.2 | -0.5 |
| Generalized anxiety disorder | 2.6 | 2.4 | 0.08 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.5 | 0.9 | 1.78 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.6 | -0.78 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.3 | 1.7 | 0.94 |
| Heart Failure | 3.9 | 1.7 | 1.29 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.6 | 0.6 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.6 | 0.33 |
| hyperglycemia | 2.1 | 2.1 | 0 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 5.5 | 5.6 | -0.02 |
| Hypothyroidism | 0.4 | 1 | -1.5 |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.6 | 3.9 | -1.44 |
| Inflammatory Bowel Disease | 7.5 | 8.2 | -0.09 |
| Insomnia | 1.9 | 3.4 | -0.79 |
| Intelligence | 1.5 | 1.5 | |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 7.4 | 6 | 0.23 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 7 | 5 | 0.4 |
| Long COVID | 6.5 | 8.1 | -0.25 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.6 | -0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 0.9 | 1.9 | -1.11 |
| ME/CFS without IBS | 1.4 | 2.4 | -0.71 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.9 | 1.33 |
| Metabolic Syndrome | 6.7 | 8 | -0.19 |
| Mood Disorders | 11.5 | 8.2 | 0.4 |
| multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
| Multiple Sclerosis | 7.1 | 5.3 | 0.34 |
| Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.5 | -10.67 |
| Neuropathy (all types) | 1.1 | 2.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 5.3 | -0.06 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.5 | 7.6 | 0.38 |
| obsessive-compulsive disorder | 5.5 | 3.5 | 0.57 |
| Osteoarthritis | 2.3 | 1.6 | 0.44 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 8.3 | 4.8 | 0.73 |
| Polycystic ovary syndrome | 6 | 3.1 | 0.94 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.2 | 2.6 | -0.18 |
| Psoriasis | 3.4 | 2.8 | 0.21 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.2 | 3.3 | 1.18 |
| Rosacea | 1 | 0.7 | 0.43 |
| Schizophrenia | 7.1 | 3.5 | 1.03 |
| scoliosis | 0.6 | 0.9 | -0.5 |
| Sjögren syndrome | 2.6 | 3 | -0.15 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 3 | 3.3 | -0.1 |
| Systemic Lupus Erythematosus | 3.1 | 1.9 | 0.63 |
| Tic Disorder | 1.4 | 1.2 | 0.17 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 4.1 | 4.2 | -0.02 |
| Type 2 Diabetes | 7.9 | 7.1 | 0.11 |
| Ulcerative colitis | 5.1 | 6.7 | -0.31 |
| Unhealthy Ageing | 3.9 | 2.3 | 0.7 |
| Vitiligo | 1.9 | 1.5 | 0.27 |
